Prescription opioid characteristics at initiation for non-cancer pain and risk of treated opioid use disorder: A population-based study

被引:6
|
作者
Papadomanolakis-Pakis, Nicholas [1 ,2 ]
Moore, Kieran M. [1 ,2 ]
Peng, Yingwei [1 ]
Gomes, Tara [3 ,4 ]
机构
[1] Queens Univ, Dept Publ Hlth Sci, 62 Fifth Field Co Lane, Kingston, ON K7L 3N6, Canada
[2] KFL&A Publ Hlth, 221 Portsmouth Ave, Kingston, ON K7M 1V5, Canada
[3] St Michaels Hosp, Li Ka Shing Knowledge Inst, 209 Victoria St, Toronto, ON M5B 1T8, Canada
[4] Univ Toronto, ICES, 155 Coll St, Toronto, ON M5T 1P8, Canada
关键词
Addiction; Opioid analgesics; Opioids; Opioid use disorder; Non-cancer pain; Pharmacoepidemiology; THERAPY; ASSOCIATION; PREVALENCE; GUIDELINE; OVERDOSE; ONTARIO; MISUSE;
D O I
10.1016/j.drugalcdep.2021.108601
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Long-term prescription opioid use has been associated with adverse health outcomes, including opioid use disorder (OUD). We examined a population of opioid na?ve individuals who initiated prescription opioids for non-cancer pain and investigated the associations between opioid prescription characteristics at initiation and time to treated OUD. Methods: We conducted a retrospective population-based cohort study in Ontario, Canada among opioid na?ve individuals aged 15 years and older dispensed an opioid for non-cancer pain between 2013 and 2016. We used the Narcotic Monitoring System to abstract opioid dispensing data. A multivariable Cox regression model was used to examine the association between average daily dose and time to treated OUD. Results: We identified 1,607,659 opioid-na?ve individuals who initiated a prescription opioid within the study period. The incidence of treated OUD within the study period was 86 cases per 100,000 person-years. Compared to an average daily dose of <20 morphine milligrams equivalent (MME), higher average daily doses at initiation were associated with greater hazard of treated OUD, 20?50 MME (HR 1.11, 95% CI: 1.02, 1.21), >50-90 MME (HR 1.29, 95% CI: 1.16, 1.44), >90-150 MME (HR 1.29, 95% CI: 1.06, 1.56), >150?200 MME (HR 2.49, 95% CI: 1.54, 4.03) and >200 MME (HR 4.15, 95% CI: 2.89, 5.97). Long-acting formulations and days? supply ?11 days were also associated with greater hazard of treated OUD. Conclusion: Prescription opioid characteristics at initiation are associated with risk of treated OUD, identifying potentially important and modifiable risk factors among people initiating opioids for non-cancer pain.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Pediatric opioid prescription rates for non-cancer pain: 2005-2014
    Pielech, M.
    Rivers, W.
    Bailey, R.
    Vowles, K.
    JOURNAL OF PAIN, 2016, 17 (04): : S86 - S87
  • [22] OPIOID ANALGESICS IN CHRONIC NON-CANCER PAIN: A QUALITY USE OF MEDICINES STUDY
    Holliday, Simon
    Magin, Parker
    Dunlop, Adrian
    Dunbabin, Janet
    Henry, Julie
    Goode, Susan
    Lintzeris, Nicholas
    Attia, John
    DRUG AND ALCOHOL REVIEW, 2011, 30 : 40 - 40
  • [23] Opioid analgesics and chronic non-cancer pain: a prescription for research in primary care
    Scherrer, Jeffrey F.
    Schneider, F. David
    Lustman, Patrick J.
    FAMILY PRACTICE, 2016, 33 (06) : 569 - 571
  • [24] Prescription of opioid analgesics for non-cancer pain in Germany: study protocol for a mixed methods analysis
    Nils Frederik Schrader
    Anja Niemann
    Christian Speckemeier
    Carina Abels
    Nikola Blase
    Godwin Denk Giebel
    Cordula Riederer
    Joachim Nadstawek
    Wolfgang Straßmeir
    Jürgen Wasem
    Silke Neusser
    Journal of Public Health, 2023, 31 : 1909 - 1919
  • [25] Prescription of opioid analgesics for non-cancer pain in Germany: study protocol for a mixed methods analysis
    Schrader, Nils Frederik
    Niemann, Anja
    Speckemeier, Christian
    Abels, Carina
    Blase, Nikola
    Giebel, Godwin Denk
    Riederer, Cordula
    Nadstawek, Joachim
    Strassmeir, Wolfgang
    Wasem, Jurgen
    Neusser, Silke
    JOURNAL OF PUBLIC HEALTH-HEIDELBERG, 2023, 31 (11): : 1909 - 1919
  • [26] Analgesic Opioid Misuse and Opioid Use Disorder among Patients with Chronic Non-Cancer Pain and Prescribed Opioids in a Pain Centre in France
    Guillou-Landreat, Morgane
    Quinio, Bertrand
    Reste, Jean Yves Le
    Goff, Delphine Le
    Fonsecca, Jerome
    Grall-Bronnec, Marie
    Dany, Antoine
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (04) : 1 - 15
  • [27] Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non-Cancer Pain
    Corriere, Meghan A.
    Daniel, Laura L.
    Dickson, Alyson L.
    Nepal, Puran
    Hall, Kathi
    Plummer, W. Dale
    Dupont, William D.
    Murray, Katherine T.
    Stein, C. Michael
    Ray, Wayne A.
    Chung, Cecilia P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (05) : 1050 - 1057
  • [28] CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN
    Corriere, M.
    Dickson, A.
    Daniel, L.
    Nepal, P.
    Hall, K.
    Plummer, W.
    Dupont, W.
    Murray, K.
    Stein, M.
    Ray, W.
    Chung, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S5 - S5
  • [29] CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN
    Corriere, M.
    Dickson, A.
    Daniel, L.
    Nepal, P.
    Hall, K.
    Plummer, W.
    Dupont, W.
    Murray, K.
    Stein, M.
    Ray, W.
    Chung, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S11 - S11
  • [30] Prenatal Opioid Use Disorder and the Risk of Congenital Anomalies in Offspring: A Population-Based Study
    Ramage, Kaylee
    Yee, Jennifer
    Srugo, Sebastian
    Little, Julian
    Liu, Shiliang
    BIRTH DEFECTS RESEARCH, 2025, 117 (02):